**EQUITY RESEARCH - RESULTS FLASH** 

# PRARAM 9 HOSPITAL

PR9 TB

THAILAND / HEALTH CARE SERVICES





**TARGET PRICE** THB24.00 **CLOSE** THB18.80 **UP/DOWNSIDE** +27.7% **TP vs CONSENSUS** +9.2%

# 1Q24 results at first glance

# PR9's core profit jumped by 46% y-y to THB159m, beating our estimate by 12%

# **Highlights**

- PR9 reported a strong core profit of THB159m for 1Q24 (+46% y-y, -15% q-q), beating our estimate by 12% due to a higher-thanexpected EBITDA margin.
- Revenue grew 12% y-y in 1Q24. Thai patient revenue grew by 10% y-y, while international patient revenue jumped by 25% y-y, led by higher patient revenue from CLMV, China and the Middle East.
- The revenue contribution from Thai patients made up a 85% proportion, and international patient revenue made up 15%.
- SG&A was flat y-y thanks to better cost control. COGS increased by 9% y-y following the revenue increase. As a result, the EBITDA margin jumped to 25% (vs 21% in 1Q23).
- 1Q24 core profit accounted for 24% of our 2024 core profit forecast of THB656m.

#### **Outlook**

We expect the strong earnings growth momentum to continue in 2Q24 due to the low base last year. In addition, PR9 has started serving Middle East patients. Thus, we expect strong international patient revenue growth post Ramadan period.

### **KEY STOCK DATA**

YE Dec (THB m)	2023	2024E	2025E	2026E
Revenue	4,202	4,633	4,915	5,214
Net profit	558	656	720	789
EPS (THB)	0.71	0.83	0.92	1.00
vs Consensus (%)	-	4.1	3.0	1.8
EBITDA	958	1,107	1,201	1,304
Recurring net profit	558	656	720	789
Core EPS (THB)	0.71	0.83	0.92	1.00
EPS growth (%)	(1.7)	17.5	9.8	9.7
Core P/E (x)	26.5	22.5	20.5	18.7
Dividend yield (%)	1.6	2.2	2.4	2.7
EV/EBITDA (x)	13.5	11.2	10.0	8.9
Price/book (x)	2.9	2.7	2.5	2.3
Net debt/Equity (%)	(37.3)	(42.7)	(46.8)	(50.7)
ROE (%)	11.4	12.4	12.6	12.9



Share price performance	1 Month	3 Month	12 Month
Absolute (%)	(2.6)	5.6	(6.0)
Relative to country (%)	(0.9)	7.1	6.9
Mkt cap (USD m)			402
3m avg. daily turnover (USI	O m)		1.0
Free float (%)			59
Major shareholder	Khunying Potja	aman Damap	ong (37%)
12m high/low (THB)		1	9.90/13.10
Issued shares (m)			786.30

Sources: Bloomberg consensus; FSSIA estimates



Teerapol Udomvej, CFA Fundamental Investment Analyst on Securities; License no. 080523 teerapol.udo@fssia.com, +66 2646 9969

Exhibit 1: PR9 – 1Q24 results summary

FY ending Dec	1Q23	2Q23	3Q23	4Q23	1Q24	Char	nge	2023	2024E
	(THB m)	(q-q %)	(y-y %)	(THB m)	(THB m)				
Sales	957	1,005	1,066	1,175	1,071	(9)	12	4,202	4,633
COGS (incl depreciation)	(657)	(688)	(714)	(761)	(715)	(6)	9	(2,820)	(3,068)
Gross profit	300	316	351	414	356	(14)	19	1,382	1,565
SG&A	(182)	(185)	(198)	(209)	(182)	(13)	(0)	(774)	(820)
Operating profit	118	132	154	205	175	(15)	48	608	745
Net other income	16	17	19	28	22	(21)	39	81	75
Interest expenses	(0)	(0)	(0)	(0)	(0)	(2)	(2)	(1)	0
Pretax profit	134	149	173	233	197	(16)	47	689	820
Income Tax	(25)	(28)	(33)	(45)	(38)	(16)	51	(131)	(164)
Core profit	109	121	140	188	159	(15)	46	558	656
Extraordinaries, GW & FX									
Reported net profit	109	121	140	188	159	(15)	46	558	656
Outstanding shares (m)	786	786	786	786	786	0	0	786	786
Pre-ex EPS (THB)	0.14	0.15	0.18	0.24	0.20	(15)	46	0.71	0.83
EPS (THB)	0.14	0.15	0.18	0.24	0.20	(15)	46	0.71	0.83
COGS excl. depreciation	(584)	(614)	(638)	(686)	(640)	(7)	10	(2,521)	(2,756)
Depreciation	(73)	(75)	(76)	(75)	(75)	(1)	2	(299)	(312)
EBITDA	207	224	249	308	271	(12)	31	988	1,131
Key ratios	(%)	(%)	(%)	(%)	(%)	(ppt)	(ppt)	(%)	(%)
Gross margin	31	31	33	35	33	(2)	2	33	34
SG&A/Revenue	19	18	19	18	17	(1)	(2)	18	18
EBITDA margin	21	22	23	26	25	(1)	4	23	24
Net profit margin	11	12	13	16	15	(1)	3	13	14
Operating stats	(%)	(%)	(%)	(%)	(%)				
OPD revenue growth y-y	6	5	4	3	13				
OPD volume growth y-y	8	4	5	4	-				
OPD revenue per head growth y-y	(2)	1	(0)	(1)	-				
IPD revenue growth y-y	(11)	1	(5)	12	11				
IPD volume growth y-y	(35)	(10)	(11)	13	-				
IPD revenue per head growth y-y	38	13	6	(1)	-				
Thai patient revenue growth y-y	(5)	4	1	6	10				
Inter patient revenue growth y-y	29	1	(5)	9	25				

Sources: PR9; FSSIA estimates

# **Financial Statements**

Praram 9 Hospital

Profit and Loss (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Revenue	4,107	4,202	4,633	4,915	5,214
Cost of goods sold	(2,724)	(2,820)	(3,068)	(3,241)	(3,424)
Gross profit	1,384	1,382	1,565	1,674	1,790
Other operating income	43	51	50	50	52
Operating costs	(735)	(774)	(820)	(855)	(891)
Operating EBITDA	991	958	1,107	1,201	1,304
Depreciation	(299)	(299)	(312)	(332)	(353)
Goodwill amortisation	-	-	-	-	-
Operating EBIT	692	659	795	869	951
Net financing costs	8	30	25	31	36
Associates	0	0	0	0	0
Recurring non-operating income	0	0	0	0	0
Non-recurring items	0	0	0	0	0
Profit before tax	700	689	820	900	987
Гах	(132)	(131)	(164)	(180)	(197)
Profit after tax	568	558	656	720	789
Minority interests	0	0	0	0	0
Preferred dividends	_	_	_	-	
Other items	-	-	-	-	
Reported net profit	568	- 558	656	720	789
		0	0	0	
Non-recurring items & goodwill (net)	0				0
Recurring net profit	568	558	656	720	789
Per share (THB)					
Recurring EPS *	0.72	0.71	0.83	0.92	1.00
Reported EPS	0.72	0.71	0.83	0.92	1.00
OPS .	0.29	0.30	0.42	0.46	0.50
Diluted shares (used to calculate per share data)	786	786	786	786	786
Growth					
Revenue (%)	37.5	2.3	10.3	6.1	6.1
Operating EBITDA (%)	67.9	(3.4)	15.5	8.5	8.6
Operating EBIT (%)	133.3	(4.7)	20.6	9.4	9.4
Recurring EPS (%)	127.8	(1.7)	17.5	9.8	9.7
Reported EPS (%)	127.8	(1.7)	17.5	9.8	9.7
Operating performance					
Gross margin inc. depreciation (%)	33.7	32.9	33.8	34.1	34.3
Gross margin exc. depreciation (%)	41.0	40.0	40.5	40.8	41.1
Operating EBITDA margin (%)	24.1	22.8	23.9	24.4	25.0
Operating EBIT margin (%)	16.8	15.7	17.2	17.7	18.2
Net margin (%)	13.8	13.3	14.2	14.6	15.1
Effective tax rate (%)	18.9	19.0	20.0	20.0	20.0
Dividend payout on recurring profit (%)	40.2	42.3	50.0	50.0	50.0
nterest cover (X)	(84.0)	(22.3)	(32.2)	(28.4)	(26.4)
	,				
nventory days	8.1	7.2	6.7	6.8	6.8
Debtor days	20.2	23.1	22.9	21.5	20.3
Creditor days	82.5	73.9	72.3	73.5	73.5
Operating ROIC (%)	18.1	17.6	20.9	23.0	25.3
ROIC (%)	17.4	16.1	18.9	20.8	22.9
ROE (%)	12.6	11.4	12.4	12.6	12.9
ROA (%)	10.5	9.3	10.3	10.5	10.8
Pre exceptional, pre-goodwill and fully diluted					
Revenue by Division (THB m)	2022	2023	2024E	2025E	2026E
OPD patient revenue	2,383	2,491	2,746	2,913	3,091
PD patient revenue	1,725	1,711	1,887	2,002	2,124
i D patient revenue	1,720	1,111	1,007	۷,002	۷, ۱۷

Sources: Praram 9 Hospital; FSSIA estimates

# **Financial Statements**

Praram 9 Hospital

Cash Flow (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Recurring net profit	568	558	656	720	789
epreciation	299	299	312	332	353
ssociates & minorities	-	-	-	-	
Other non-cash items	10	10	0 54	0 35	37
Change in working capital	(5) <b>871</b>	(23) <b>844</b>	1,021	1,087	1,179
Cash flow from operations Capex - maintenance	(140)	(326)	(330)	(350)	(371
Capex - new investment	(140)	(320)	(330)	(330)	(371
Net acquisitions & disposals	(150)	(100)	0	0	(
Other investments (net)	(100)	(100)	-	-	`
Cash flow from investing	(290)	(426)	(330)	(350)	(371
Dividends paid	(110)	(234)	(236)	(328)	(360
Equity finance	0	0	0	0	(000)
Debt finance	2	1	0	0	(
Other financing cash flows	0	0	0	0	(
Cash flow from financing	(108)	(233)	(236)	(328)	(360
Non-recurring cash flows	· · -	• •			
Other adjustments	0	0	0	0	(
Net other adjustments	0	0	0	0	(
Movement in cash	473	184	456	409	448
Free cash flow to firm (FCFF)	581.44	418.17	691.50	736.80	808.12
Free cash flow to equity (FCFE)	582.47	418.73	691.50	736.80	808.12
Per share (THB)					
FCFF per share	0.74	0.53	0.88	0.94	1.03
FCFE per share	0.74	0.53	0.88	0.94	1.03
Recurring cash flow per share	1.11	1.10	1.23	1.34	1.45
Salance Sheet (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Fangible fixed assets (gross)	5,638	5,898	6,228	6,578	6,949
_ess: Accumulated depreciation  Fangible fixed assets (net)	(2,322) <b>3,315</b>	(2,556) <b>3,343</b>	(2,867) <b>3,361</b>	(3,199) <b>3,379</b>	(3,552 <b>3,39</b> 7
ntangible fixed assets (net)	0,313	0	0	0,379	3,39
Long-term financial assets	-	-	-	-	
nvest. in associates & subsidiaries	154	254	254	254	25
Cash & equivalents	1,717	1,901	2,357	2,766	3,21
A/C receivable	243	290	290	290	29
nventories	51	48	53	56	5
Other current assets	12	12	13	14	1:
Current assets	2,023	2,251	2,713	3,125	3,57
Other assets	65	62	62	62	6
Total assets	5,558	5,910	6,389	6,820	7,29
Common equity	4,735	5,080	5,499	5,892	6,32
Minorities etc.	0	0	0	0	
Total shareholders' equity	4,735	5,080	5,499	5,892	6,32
ong term debt	8	9	9	9	
Other long-term liabilities	209	195	195	195	19
Long-term liabilities	217	204	204	204	20
A/C payable	499	522	570	602	63
Short term debt	0	0	0	0	
Other current liabilities	106	105	115	122	13
Current liabilities	606	626	686	724	76
Total liabilities and shareholders' equity	5,558	5,910	6,389	6,820	7,29
Net working capital	(299)	(276)	(330)	(365)	(402
nvested capital	3,235	3,382	3,347	3,330	3,31
Includes convertibles and preferred stock which is beir	ng treated as debt				
Per share (THB)					
Book value per share	6.02	6.46	6.99	7.49	8.0
Tangible book value per share	6.02	6.46	6.99	7.49	8.0
Financial strength					
Net debt/equity (%)	(36.1)	(37.3)	(42.7)	(46.8)	(50.7
Net debt/total assets (%)	(30.8)	(32.0)	(36.8)	(40.4)	(44.0
Current ratio (x)	3.3	3.6	4.0	4.3	4.
CF interest cover (x)	(69.7)	(13.2)	(27.0)	(23.0)	(21.5
/aluation	2022	2023	2024E	2025E	2026
Recurring P/E (x) *	26.0	26.5	22.5	20.5	18.
					23.
Recurring P/E @ target price (x) *	<b>33.2</b>	<b>33.8</b>	<b>28.8</b>	<b>26.2</b>	
Reported P/E (x)	26.0	26.5	22.5	20.5	18
Dividend yield (%)	1.5	1.6	2.2	2.4	2
Price/book (x)	3.1	2.9	2.7	2.5	2
Price/tangible book (x)	3.1	2.9	2.7	2.5	2
EV/EBITDA (x) **	13.2	13.5	11.2	10.0	8
7\/CDITDA @ 44 (-) ++				1.7 /	12.
EV/EBITDA @ target price (x) ** EV/invested capital (x)	17.3 4.0	17.7 3.8	14.9 3.7	13.4 3.6	3.

Sources: Praram 9 Hospital; FSSIA estimates

# Praram 9 Hospital PCL (PR9 TB)



# **Exhibit 2: FSSIA ESG score implication**

54.08 /100

Rating	Score	Implication
****	>79-100	Leading its industry peers in managing the most significant ESG risks which not only better cost efficiency but also lead to higher profitability.
***	>59-79	A mixed track record of managing the most significant ESG risks and opportunities relative to industry peers.
***	>39-59	Relevant ESG materiality matrix has been constructively addressed, well-managed and incorporated into day-to-day operations, in which targets and achievements are evaluated annually.
**	>19-39	Relevant ESG materiality matrix has been identified with key management in charge for progress to be followed up on and to provide intensive disclosure. Most targets are conventional and achievable.
*	1-19	The company has adopted the United Nations Sustainable Development Goals (UN SDGs), established sustainability management guidelines and fully complies with regulations or ESG suggested guidance from related organizations such as the SET and SEC.

Sources: FSSIA estimates

# Exhibit 3: ESG – peer comparison

	FSSIA		Domestic ratings					Global ratings						Bloomberg	
	ESG score	DJSI	SET THSI	THSI	CG score	AGM level	Thai CAC	Morningstar ESG risk	ESG Book	MSCI	Moody's	Refinitiv	S&P Global	ESG score	Disclosure score
SET100	69.20	5.34	4.40	4.40	4.76	4.65	3.84	Medium	51.76	BBB	20.87	58.72	63.91	3.72	28.17
Coverage	67.12	5.11	4.15	4.17	4.83	4.71	3.53	Medium	52.04	ВВ	16.97	56.85	62.09	3.40	31.94
BCH	39.71				4.00	5.00	Certified	High	48.21			27.19	18.00	3.52	47.60
BDMS	74.00	Υ	Y	Y	5.00	4.00		Medium	61.06	AA	34.00	59.83	72.00	3.45	58.92
ВН	51.21				4.00	4.00		Medium	64.29	Α	29.00	59.03	27.00	5.08	47.79
CHG	38.25				4.00	5.00		High	55.35			59.57	21.00	2.34	50.24
PR9	54.08		Y	Υ	5.00	5.00	Certified	High	71.12			62.39		2.43	37.90
PRINC	18.00				4.00	4.00	Certified								
RAM	11.75				3.00			High							
THG	18.75				5.00	5.00		High							
VIBHA	20.88				4.00	3.00	Declared	High					17.00		

Sources: SETTRADE.com; FSSIA's compilation

# Exhibit 4: ESG score by Bloomberg

FY ending Dec 31	FY 2020	FY 2021	FY 2022
ESG financial materiality scores - ESG score	_	2.33	2.43
BESG environmental pillar score	_	2.56	2.18
BESG social pillar score	_	1.36	1.52
BESG governance pillar score	_	4.13	4.46
ESG disclosure score	_	37.90	37.90
Environmental disclosure score	_	11.78	11.78
Social disclosure score	_	20.68	20.68
Governance disclosure score	_	81.10	81.10
Environmental			
Emissions reduction initiatives	No	Yes	Yes
Climate change policy	No	Yes	Yes
Climate change opportunities discussed	No	No	No
Risks of climate change discussed	No	No	No
GHG scope 1	_	0	0
GHG scope 2 location-based	_	4	6
GHG Scope 3	_	0	5
Carbon per unit of production	_	_	_
Biodiversity policy	No	No	No
Energy efficiency policy	No	Yes	Yes
Total energy consumption	_	7	13
Renewable energy use	_	_	_
Electricity used	_	_	_
Fuel used - natural gas	_	_	_

 $Sources: Bloomberg; FSSIA's \ compilation$ 

**Exhibit 5: ESG score by Bloomberg** (cont.)

Fuel used - crude oil/diesel			
	No	No	No
Waste reduction policy	No	Yes	Yes
Hazardous waste	_	_	_
Total waste	_	_	_
Waste recycled	_	_	_
Waste sent to landfills	_	_	_
Environmental supply chain management	No	No	No
Water policy	No	Yes	Yes
Water consumption	_	60	151
Social			
Human rights policy	Yes	Yes	Yes
Policy against child labor	No	Yes	Yes
Quality assurance and recall policy	No	Yes	Yes
Consumer data protection policy	No	Yes	Yes
Equal opportunity policy	Yes	Yes	Yes
Gender pay gap breakout	No	No	No
Pct women in workforce	_	_	_
Pct disabled in workforce	_	_	_
Business ethics policy	No	Yes	Ye
Anti-bribery ethics policy	Yes	Yes	Ye
Health and safety policy	No	Yes	Ye
Lost time incident rate - employees	_	_	_
Total recordable incident rate - employees	_	1	(
Training policy	Yes	Yes	Ye
Fair remuneration policy	No	No	N
Number of employees – CSR	2,083	1,987	2,01
Employee turnover pct	_	11	1:
Total hours spent by firm - employee training	14,566	13,462	66,85
Social supply chain management	No	No	No
Governance			
Board size	10	10	9
No. of independent directors (ID)	4	7	(
No. of women on board	2	2	:
No. of non-executive directors on board	7	7	
Company conducts board evaluations	Yes	Yes	Ye
No. of board meetings for the year	7	7	,
Board meeting attendance pct	97	100	8
Board duration (years)	3	3	;
Director share ownership guidelines	No	No	Ne
Age of the youngest director	56	56	5
Age of the oldest director	72	73	7-
No. of executives / company managers	7	5	
No. of female executives	2	0	
Executive share ownership guidelines	No	No	N
Size of audit committee	3	3	
No. of ID on audit committee	3	3	
Audit committee meetings	4	4	
Audit meeting attendance %	100	100	10
Size of compensation committee	3	3	
No. of ID on compensation committee	3	2	
No. of compensation committee meetings	2	2	
Compensation meeting attendance %	83	100	10
Size of nomination committee	3	3	
Size of nonination committee			
No. of nomination committee meetings	2	2	
	2 83	2 100	100

Sources: Bloomberg; FSSIA's compilation

# **Disclaimer for ESG scoring**

ESG score	Methodolog	у			Rating					
The Dow Jones Sustainability Indices ( <u>DJSI</u> ) By S&P Global	process bas from the ann	ed on the compute of the computer of the compu	transparent, rules-based panies' Total Sustainabil al Corporate Sustainabili anies within each industr	ity Scores resulting ty Assessment (CSA).	Sustainability A ESG Score of I	Assessment (C ess than 45% ny are disqual	he annual S&P ( SA) for DJSI. Co of the S&P Glob ified. The constit iverse.	ompanies with al ESG Score	an S&P Globa of the highest	
Sustainability Investment List ( <u>THSI</u> ) by The Stock Exchange of Thailand ( <u>SET</u> )	managing be Candidates 1) no irregul float of >150 up capital. S 70%; 2) inde wrongdoing	usiness with tra must pass the ar trading of the shareholders, some key disque ependent direct related to CG,	lity in Environmental and ansparency in Governand preemptive criteria, with e board members and ex- , and combined holding in alifying criteria include: tors and free float violation social & environmental in arnings in red for > 3 year	ce, updated annually. two crucial conditions: kecutives; and 2) free nust be >15% of paid- 1) CG score of below on; 3) executives' mpacts; 4) equity in	To be eligible for <u>THSI inclusion</u> , verified data must be scored at a minimum of 50% for each indicator, unless the company is a part of DJSI during the assessment year. The scoring will be fairly weighted against the nature of the relevant industry and materiality. <u>SETTHSI Index</u> is extended from the THSI companies whose 1) market capitalization > THB5b (~USD150b); 2) free float >20%; and 3) liquidity >0.5% of paid-up capital for at least 9 out of 12 months. The SETTHSI Index is a market capitalisation-weighted index, cap 5% quarterly weight a maximum, and no cap for number of stocks.					
CG Score by Thai nstitute of Directors Association Thai IOD)	annually by Thailand (St	the Thai IOD, v	n in sustainable developr with support from the Sto s are from the perspectiv s.	ck Exchange of	Good (80-89), and not rated f equitable treate	3 for Good (70 or scores belo ment of sharel 25%); 4) disclo	ories: 5 for Excel 0-79), 2 for Fair (6 w 50. Weightings nolders (weight 2 ssure & transpare	60-69), 1 for P s include: 1) th 5% combined	ass (60-69), le rights; 2) an ); 3) the role o	
AGM level By Thai nvestors Association (TIA) with support from the SEC	treatment ar transparent out of five th criteria cove date (45%), circulation of s exercised. The and verifiability	e incorporated and sufficiently e CG componer AGM procedu and after the nation information information in the second assessey; and 3) openned	which shareholders' rights into business operations or disclosed. All form impoents to be evaluated annures before the meeting ineeting (10%). (The first align for voting; and 2) facilitations of the ease of attending mass for Q&A. The third involvess, resolutions and voting res	s and information is ortant elements of two ually. The assessment (45%), at the meeting ssesses 1) advance ing how voting rights can be eetings; 2) transparency s the meeting minutes that			ofour categories: (80-89), and not		· //	
Fhai CAC By Thai Private Sector Collective Action Against Corruption CAC)	establishme policies. The (Companies of Declaration of Certification, in managers and	nt of key control c Certification is eciding to become Intent to kick off including risk asset	Checklist include corruptions, and the monitoring as good for three years. The activities are a CAC certified member stain 18-month deadline to subsessment, in place of policy are ablishment of whistleblowing at stakeholders.)	nd developing of  art by submitting a mit the CAC Checklist for ad control, training of	The document will be reviewed by a committee of nine professionals. A passed Checklist will move for granting certification by the CAC Council approvals whose members are twelve highly respected individuals in professionalism and ethical achievements.					
Morningstar Sustainalytics	based on an risk is unma	assessment on aged. <i>Sources</i>	sk rating provides an ove of how much of a compar of to be reviewed include corp- ier media, NGO reports/webs	ny's exposure to ESG orate publications and			score is the sum higher ESG risk		ed risk. The	
	information, co		k, ESG controversies, issuer		<b>NEGL</b> 0-10	Low 10-20	Medium 20-30	<b>High</b> 30-40	Severe 40+	
ESG Book	positioned to the principle helps explai over-weighti	o outperform ov of financial ma n future risk-ad	ustainable companies the ver the long term. The materiality including inform tjusted performance. Mat the higher materiality and rly basis.	ethodology considers ation that significantly teriality is applied by	scores using m	ateriality-base	ated as a weight ad weights. The s ndicating better p	core is scaled		
MSCI			measure a company's mand laggards according to						nethodology to	
	AAA	8.571-10.000								
	AA	7.143-8.570	Leader:	leading its industry in m	anaging the most s	ignilicant ESG fi	sks and opportunitie	55		
	Α	5.714-7.142								
	BBB	4.286-5.713	Average:	a mixed or unexceptional industry peers	nexceptional track record of managing the most significant ESG risks and opportunities relative s					
	ВВ	2.857-4.285		, .						
	В	1.429-2.856	Laggard:	lagging its industry base	ed on its high expos	sure and failure t	o manage significar	nt ESG risks		
	ccc	0.000-1.428	_~3Juiu.			a landio t	go o.griinodi	3		
Moody's ESG olutions	believes tha	t a company in	ree to which companies tegrating ESG factors int or shareholders over the i	to its business model and						
Refinitiv ESG rating	based on pu	ıblicly available	and objectively measure and auditable data. The ta publicly. <i>(Score ratings a</i>	score ranges from 0 to	100 on relative E	SG performar	nce and insufficie	nt degree of t		
S&P Global			e is a relative score mea in the same industry clas				of ESG risks, op	portunities, ar	d impacts	
Bloomberg	ESG Score		score is based on Bloor		ıncial materiality.	The score is	a weighted gener	ralized mean	power mean)	
		score is based on Bloomberg's view of ESG financial materiality. The score is a weighted generalized mean (power mean) of Pillar Scores, where the weights are determined by the pillar priority ranking. Values range from 0 to 10; 10 is the best.  SG Disclosure Score  Disclosure of a company's ESG used for Bloomberg ESG score. The score ranges from 0 for none to 100 for disclosure of								

Rating regarding the sustainable development of Thai listed companies, both on the SET and MAI, are publicly available on the website of the Securities and Exchange Commission of Thailand (SEC). Currently, ratings available are 1) "CG Score"; 2) "AGM Level"; 3) "Thai CAC"; and 4) THSI. The ratings are updated on an annual basis. FSSIA does not confirm nor certify the accuracy of such ratings.

Source: FSSIA's compilation

#### **GENERAL DISCLAIMER**

# ANALYST(S) CERTIFICATION

#### Teerapol Udomvej, CFA FSS International Investment Advisory Securities Co., Ltd

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Securities Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSSIA makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSSIA has no intention to solicit investors to buy or sell any security in this report. In addition, FSSIA does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

### History of change in investment rating and/or target price



Date	Rating	Target price	Date	Rating	Target price	Date	Rating	Target price
19-May-2021 16-Jul-2021 10-Jan-2022	BUY BUY BUY	13.00 14.00 15.00	22-Apr-2022 12-Jul-2022 11-Oct-2022	BUY BUY BUY	16.50 18.00 21.00	17-Jan-2023 10-Apr-2024	BUY BUY	22.00 24.00

Teerapol Udomvej, CFA started covering this stock from 30-Jul-2020

Price and TP are in local currency

Source: FSSIA estimates

Company	Ticker	Price	Rating	Valuation & Risks
Praram 9 Hospital	PR9 TB	THB 18.80	BUY	Downside risks to our DCF-based target price include 1) weak patient volumes following the economic slowdown; 2) regulatory risks from drug price and medical bill controls; and 3) higher-than-expected expenses from its new building.

Source: FSSIA estimates

#### **Additional Disclosures**

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited.

All share prices are as at market close on 13-May-2024 unless otherwise stated.

### RECOMMENDATION STRUCTURE

## Stock ratings

Stock ratings are based on absolute upside or downside, which we define as (target price\* - current price) / current price.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

\* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

### **Industry Recommendations**

Overweight. The analyst expects the fundamental conditions of the sector to be positive over the next 12 months.

Neutral. The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months.

Underweight. The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

#### **Country (Strategy) Recommendations**

**Overweight (O).** Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

**Neutral (N).** Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

**Underweight (U).** Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.